Km. Wasan et G. Lopezberestein, DIVERSITY OF LIPID-BASED POLYENE FORMULATIONS AND THEIR BEHAVIOR IN BIOLOGICAL-SYSTEMS, European journal of clinical microbiology & infectious diseases, 16(1), 1997, pp. 81-92
Patients with cancer and infectious diseases often display dyslipidemi
as that result in changes in their plasma lipoprotein-lipid compositio
n. It is likely that the interactions of liposomal polyenes with plasm
a lipoproteins may be responsible for the far different pharmacokineti
cs and pharmacodynamics of these compounds when they are administered
to infected patients rather than to animals or healthy volunteers. Amp
hotericin B (AmpB) and nystatin are examples of such polyenes. Amphote
ricin B initially distributes with the high-density lipoprotein (HDL)
fraction upon incubation in plasma. Over time, AmpB redistributes from
HDLs to low-density lipoproteins (LDLs). This redistribution appears
to be regulated by lipid transfer protein. However, when AmpB is incor
porated into liposomes composed of negatively or positively charged ph
ospholipids, not only is the capability of LTP to transfer AmpB from H
DL to LDL diminished, but AmpB remains retained with only the HDL frac
tion. However, when liposomal nystatin is incubated in plasma, over 50
% of nystatin distributes with HDLs. Over time, nystatin redistributes
from HDL to the lipoprotein-deficient plasma fraction, which is compo
sed of mainly aqueous plasma proteins. The lipid composition selected
for the drug appears to be a vital constituent in regulating the drug'
s interaction with biological fluids, Furthermore, liposome (or liposo
mal particle) size, fluidity, and other physiochemical characteristics
also play a role in altering the pharmacokinetics and pharmacological
effects of lipid-based drug formulations. Armed with this understandi
ng, a rational approach to clinical development of these formulations
could be facilitated.